Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Metformin – Forschungsarchiv – Seite 35 von 35 | SupStack

Metformin – Forschungsarchiv

Studien 2651–2685 von 2685, neueste zuerst

Die 1000 neuesten Studien – mit Evidenz-Zusammenfassung, Filtern und Suche – stehen auf der Hauptseite. Dieses Archiv listet die übrigen, 50 pro Seite. Zurück zur Hauptseite

2651RCT1993

Nagi DK, Yudkin JS · Diabetes Care (1993)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

Metformin – Forschungsarchiv

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

Short-term effects of metformin on insulin sensitivity and sodium homeostasis in essential hypertensives.

Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.

The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes.

Comparison of combined therapies in treatment of secondary failure to glyburide.

Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM.

Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide.

BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance.

The insulin sparing effect of metformin in insulin-treated diabetic patients.

Double-blind evaluation of efficacy and tolerability of metformin in NIDDM.

Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus.

Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus.

Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.

[Glycemic equilibrium and weight evolution in diabetics taking metformin].

Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy?

Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.

Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients.

Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus.

Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes.

Insulin and sulphonylurea in the therapy of type 2 diabetes.

Comparison of tolbutamide and metformin in elderly diabetic patients.

Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.

Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial.

Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus.

The hyperlactatemic effect of biguanides: a comparison between phenformin and metformin during a 6-month treatment.

Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects.

[Value of combined subcutaneous infusion of insulin and metformin in 10 insulin-dependent obese diabetics].

Effects of metformin treatment on erythrocyte insulin binding in normal weight subjects, in obese non diabetic subjects, in type 1 and type 2 diabetic patients.

Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products.

Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease.

The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin?

The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action. A drug interaction study.

Studies on juvenile--type diabetes in children. Assessment of control under treatment with constant and variable doses of insulin with or without addition of biguanides.

Comparison of fenfluramine and metformin in treatment of obesity.

Weight reduction in obesity.